Published in Arch Gen Psychiatry on July 01, 1998
Examination of a Soy-Based Supplement for Major Depression | NCT00042380
The enduring effects of abuse and related adverse experiences in childhood. A convergence of evidence from neurobiology and epidemiology. Eur Arch Psychiatry Clin Neurosci (2005) 7.21
The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord (2008) 5.33
Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA (2011) 4.75
Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care (2012) 3.53
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Depression and incident stroke in women. Stroke (2011) 2.47
Psychological sequelae resulting from the 2004 Florida hurricanes: implications for postdisaster intervention. Am J Public Health (2007) 2.40
Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One (2011) 2.30
The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry (2013) 2.17
Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry (2010) 2.15
Does depression predict coronary heart disease and cerebrovascular disease equally well? The Health and Social Support Prospective Cohort Study. Int J Epidemiol (2010) 1.84
Intra-individual variability in sleep duration and fragmentation: associations with stress. Psychoneuroendocrinology (2009) 1.67
Diagnosis and management of depression in primary care: a clinical update and review. CMAJ (2002) 1.64
Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress (2009) 1.61
Heartache and heartbreak--the link between depression and cardiovascular disease. Nat Rev Cardiol (2012) 1.55
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience (2013) 1.55
Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial. BMC Psychiatry (2007) 1.52
Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study. Biol Psychiatry (2009) 1.46
Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: A report from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Arch Gen Psychiatry (2009) 1.45
Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo-pituitary-adrenal axis. Am J Geriatr Psychiatry (2007) 1.43
VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol (2007) 1.41
National Patterns of Medication Treatment for Depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry (2001) 1.35
Do experiences of racial discrimination predict cardiovascular disease among African American men? The moderating role of internalized negative racial group attitudes. Soc Sci Med (2010) 1.35
"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol (2005) 1.31
The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry (2009) 1.29
Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol (2009) 1.27
Depressive symptoms and increased visceral fat in middle-aged women. Psychosom Med (2009) 1.27
Pathways linking socioeconomic status to obesity through depression and lifestyle factors among young US adults. J Affect Disord (2009) 1.26
Arterial endothelial function is impaired in treated depression. Heart (2002) 1.25
Inflammatory dietary pattern and risk of depression among women. Brain Behav Immun (2013) 1.22
High activity of acid sphingomyelinase in major depression. J Neural Transm (Vienna) (2005) 1.21
Relationships between cardiovascular disease risk factors and depressive symptoms as predictors of cardiovascular disease events in women. J Womens Health (Larchmt) (2011) 1.21
Neurophysiological and behavioral responses to music therapy in vegetative and minimally conscious States. Front Hum Neurosci (2013) 1.21
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
The role of cardiovascular disease in the identification and management of depression by primary care physicians. Am J Geriatr Psychiatry (2006) 1.17
Integrating co-morbid depression and chronic physical disease management: identifying and resolving failures in self-regulation. Clin Psychol Rev (2008) 1.16
Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry (2005) 1.16
Mind matters: the importance of mental disorders in public health's 21st century mission. Am J Public Health (1999) 1.13
Air pollution and symptoms of depression in elderly adults. Environ Health Perspect (2012) 1.13
Lack of a close confidant, but not depression, predicts further cardiac events after myocardial infarction. Heart (2004) 1.12
Incomplete response in late-life depression: getting to remission. Dialogues Clin Neurosci (2008) 1.10
Depression and cardiovascular health care costs among women with suspected myocardial ischemia: prospective results from the WISE (Women's Ischemia Syndrome Evaluation) Study. J Am Coll Cardiol (2009) 1.10
Affective style and in vivo immune response: neurobehavioral mechanisms. Proc Natl Acad Sci U S A (2003) 1.09
Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart (2000) 1.08
Depression, healthcare utilization, and death in heart failure: a community study. Circ Heart Fail (2013) 1.04
Should global burden of disease estimates include depression as a risk factor for coronary heart disease? BMC Med (2011) 1.04
Mental disorders and cardiovascular disease among adults in the United States. J Psychiatr Res (2008) 1.03
The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med (2013) 1.02
Pessimistic, anxious, and depressive personality traits predict all-cause mortality: the Mayo Clinic cohort study of personality and aging. Psychosom Med (2009) 1.02
Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom Med (2008) 1.01
Prevalence and correlates of poor self-rated health in the United States: the national elder mistreatment study. Am J Geriatr Psychiatry (2010) 1.00
Depression and cardiac function in patients with stable coronary heart disease: findings from the Heart and Soul Study. Psychosom Med (2008) 1.00
Psychological distress, physical illness, and risk of coronary heart disease. J Epidemiol Community Health (2005) 0.99
Health status and suicide in the second half of life. Int J Geriatr Psychiatry (2010) 0.99
Depression and whole blood serotonin in patients with coronary heart disease from the Heart and Soul Study. Psychosom Med (2009) 0.98
The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2009) 0.96
Citalopram intervention for hostility: results of a randomized clinical trial. J Consult Clin Psychol (2009) 0.96
Psychological factors and coronary heart disease. ARYA Atheroscler (2013) 0.96
Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies. Mol Psychiatry (2013) 0.95
Mediation and modification of the association between hopelessness, hostility, and progression of carotid atherosclerosis. J Behav Med (2005) 0.95
Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res (2014) 0.94
Scared to death: results from the Health, Aging, and Body Composition study. Am J Geriatr Psychiatry (2007) 0.94
Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease. Front Neuroendocrinol (2013) 0.93
Interpersonal violence, PTSD, and inflammation: potential psychogenic pathways to higher C-reactive protein levels. Cytokine (2013) 0.93
Depression in patients with cardiovascular disease. Cardiol Res Pract (2012) 0.93
Depressive symptoms and cardiovascular mortality in older black and white adults: evidence for a differential association by race. Circ Cardiovasc Qual Outcomes (2011) 0.93
Physical health behaviours and health locus of control in people with schizophrenia-spectrum disorder and bipolar disorder: a cross-sectional comparative study with people with non-psychotic mental illness. BMC Psychiatry (2011) 0.93
Cardiovascular Disease in Women: Clinical Perspectives. Circ Res (2016) 0.92
Sex-specific association of depression and a haplotype in leukotriene A4 hydrolase gene. Psychosom Med (2009) 0.92
Cynical hostility, depressive symptoms, and the expression of inflammatory risk markers for coronary heart disease. J Behav Med (2003) 0.92
History of manic and hypomanic episodes and risk of incident cardiovascular disease: 11.5 year follow-up from the Baltimore Epidemiologic Catchment Area Study. J Affect Disord (2010) 0.92
Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One (2013) 0.92
The role of perinatal problems in risk of co-morbid psychiatric and medical disorders in adulthood. Psychol Med (2007) 0.91
Structural plasticity of the adult brain: how animal models help us understand brain changes in depression and systemic disorders related to depression. Dialogues Clin Neurosci (2004) 0.90
Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J Psychiatry Neurosci (2016) 0.90
DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. PLoS One (2012) 0.90
Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem (2004) 0.90
Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim Care Companion CNS Disord (2013) 0.90
Major depression, depression treatment and quality of primary medical care. Gen Hosp Psychiatry (2007) 0.90
Temporal relationships between depressive symptoms and white matter hyperintensities in older men and women. Int J Geriatr Psychiatry (2012) 0.89
Absence of relation between depressive symptoms and carotid intimal medial thickness in the Baltimore Longitudinal Study of Aging. Psychosom Med (2008) 0.89
The uncharted waters of emotion: ethnicity, trait emotion and emotion expression in older adults. J Cross Cult Gerontol (2002) 0.89
Decreased neuroautonomic complexity in men during an acute major depressive episode: analysis of heart rate dynamics. Transl Psychiatry (2011) 0.89
Chronic diseases, lack of medications, and depression among Syrian refugees in Jordan, 2013-2014. Prev Chronic Dis (2015) 0.89
The mechanism by which moderate alcohol consumption influences coronary heart disease. Nutr J (2015) 0.88
Association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: the Fukuoka diabetes registry. PLoS One (2013) 0.88
Depression and quality of life before and after breast cancer diagnosis in older women from the Women's Health Initiative. J Cancer Surviv (2015) 0.87
Multisystem resiliency moderates the major depression-telomere length association: findings from the Heart and Soul Study. Brain Behav Immun (2013) 0.87
Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. Cardiovasc Psychiatry Neurol (2009) 0.87
Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications. Vasc Health Risk Manag (2011) 0.86
Cardiac anxiety in patients self-referred for electron beam tomography. J Behav Med (2003) 0.86
Vascular growth factors in neuropsychiatry. Cell Mol Life Sci (2013) 0.86
Influence of sex and stress exposure across the lifespan on endophenotypes of depression: focus on behavior, glucocorticoids, and hippocampus. Front Neurosci (2015) 0.86
Circadian affective, cardiopulmonary, and cortisol variability in depressed and nondepressed individuals at risk for cardiovascular disease. J Psychiatr Res (2007) 0.85
Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression. Prim Care Companion J Clin Psychiatry (2003) 0.85
Clinical depression, antidepressant use and risk of future cardiovascular disease. Eur J Epidemiol (2013) 0.85
Cardiovascular disease and psychiatric comorbidity: the potential role of perseverative cognition. Cardiovasc Psychiatry Neurol (2009) 0.85
Sex differences in mood disorders: perspectives from humans and rodent models. Biol Sex Differ (2014) 0.84
The Relationship between Vascular Function and the Autonomic Nervous System. Ann Vasc Dis (2014) 0.84
Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci (2008) 0.84
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med (2000) 10.25
The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry (2001) 7.80
Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 7.21
The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature (1992) 5.71
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry (2001) 4.36
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev (1991) 3.07
Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry (2009) 2.94
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem (1994) 2.77
Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety (2000) 2.76
Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res (2000) 2.45
Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry (2000) 2.40
Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med (1999) 2.36
Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med (2002) 2.34
Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta (1992) 2.33
Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A (1996) 2.30
Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry (2000) 2.27
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther (1997) 2.16
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry (2001) 2.05
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am (1998) 1.85
Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry (2008) 1.82
Factors influencing the epidemiology of Helicobacter pylori infection in children. Pediatrics (1991) 1.82
Exaggerated platelet reactivity in major depression. Am J Psychiatry (1996) 1.72
Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry (1995) 1.72
Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry (1997) 1.62
Apolipoprotein E-epsilon 4 frequency in geriatric depression. Biol Psychiatry (1996) 1.56
"Normal pressure" pseudotumor cerebri. J Neuroophthalmol (1996) 1.55
Personality disorder in patients infected with HIV: a controlled study with implications for clinical care. Am J Psychiatry (1993) 1.53
The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry (1999) 1.52
Hypercortisolemia and hippocampal changes in depression. Psychiatry Res (1993) 1.52
Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology (2001) 1.51
Long-term behavioral effects of repetitive pain in neonatal rat pups. Physiol Behav (1999) 1.51
Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry (2000) 1.49
Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry (1993) 1.49
Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology (1996) 1.48
Behavioral stimulation associated with risperidone initiation. Am J Psychiatry (1995) 1.43
The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry (2009) 1.43
Magnetic resonance imaging of the caudate nuclei in depression. Preliminary observations. Arch Gen Psychiatry (1992) 1.41
Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. J Clin Psychiatry (1992) 1.39
Mobile reactive centre of serpins and the control of thrombosis. Nature (1991) 1.36
Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch Gen Psychiatry (1997) 1.36
Neurotensin and dopamine interactions. Pharmacol Rev (2001) 1.35
Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry (1999) 1.35
Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol (1996) 1.33
The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Ann N Y Acad Sci (1997) 1.32
Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci (1986) 1.30
Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (1976) 1.29
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther (2007) 1.26
A magnetic resonance imaging study of putamen nuclei in major depression. Psychiatry Res (1991) 1.26
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety (2000) 1.25
Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry (1994) 1.24
Reforming Georgia's mental health system. Community Ment Health J (1995) 1.23
Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol (2000) 1.20
Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Womens Ment Health (2003) 1.20
Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci (1991) 1.19
Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci (1990) 1.18
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Psychopharmacol Bull (1997) 1.18
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet (2001) 1.18
Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry (2008) 1.18
Assessment and treatment of depression in the cancer patient. J Psychosom Res (1998) 1.17
Pituitary size in depression. J Clin Endocrinol Metab (1991) 1.16
Elevated substance P levels in HIV-infected men. AIDS (2001) 1.16
Women at risk for postpartum-onset major depression. Am J Obstet Gynecol (1995) 1.15
Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry (2000) 1.12
The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp (1993) 1.11
Coping with the threat of AIDS: the role of social support. Am J Psychiatry (1992) 1.10
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry (1997) 1.10
Depression and cardiac disease. Depress Anxiety (1998) 1.09
Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry (1995) 1.09
Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. Psychol Med (2012) 1.08
Psychiatric morbidity in endocrine disorders. Psychiatr Clin North Am (1998) 1.08
Depression during pregnancy and the puerperium. J Clin Psychiatry (1997) 1.07
Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur J Pharmacol (2000) 1.07
Contemporary management of depression. Am J Med (1994) 1.07
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem (1993) 1.06
Corticotropin releasing factor (CRF): studies in alcohol preferring and non-preferring rats. Psychopharmacology (Berl) (1992) 1.04
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry (2001) 1.04
Detection and diagnosis of psychiatric disorders in primary medical care settings. Med Clin North Am (2001) 1.04
Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates. Biol Psychiatry (2001) 1.03
Neurotensin blocks certain amphetamine-induced behaviours. Nature (1981) 1.02
Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry (1997) 1.02
Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res Bull (1994) 1.02
Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry (1980) 1.01
Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. Arch Gen Psychiatry (1998) 1.01
Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest (1994) 1.01
Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res (1977) 1.01
Elevated CSF CRF in suicide victims. Biol Psychiatry (1989) 1.01
Subcortical hyperintensities on brain magnetic resonance imaging: a comparison between late age onset and early onset elderly depressed subjects. Neurobiol Aging (1991) 1.01
The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry (1989) 1.01
CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry (1987) 1.01
Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiatry Med (1990) 1.00
Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry Suppl (1996) 0.99